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Abstract
Background—Influenza is a common cause of severe respiratory illness, but risk factors for 
hospitalisation in low income settings with a high HIV prevalence are not well described. We 
aimed to assess risk factors associated with influenza-associated severe acute respiratory illness 
(SARI) hospitalisation in South Africa.
Methods—We conducted a case-population study using data on risk conditions in patients 
hospitalised with SARI and the national prevalence of these conditions. Data on hospitalised cases 
were from the national SARI surveillance program while data on the referent population were 
from the latest national census or health and demographic surveillance surveys.
Findings—From 2009 to 2012, we identified 3646 (7.9%) of 46,031 enrolled cases of SARI that 
were associated with influenza infection. Risk factors associated with hospitalisation included 
previous history of smoking [case-population ratio (CPR) 3.82, 95% confidence interval (CI) 3.5–
4.16], HIV infection (CPR 3.61, 95% CI 3.5–3.71), asthma (CPR 2.45, 95% CI 2.19–2.73), 
previous history of hospital admission in the past 12 months (CPR 2.07, 95% CI 1.92–2.23), and 
tuberculosis (CPR 1.85, 95% CI 1.68–2.02). When stratified by age, there is increased risk of 
hospitalisation in those ≤5 years of age (CPR 3.07, 95% CI 2.93–3.21) and among those 35 years 
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of age and above (CPR 1.23, 95% CI 1.28–1.18). Male sex (CPR 0.85, 95% CI 0.82–0.88) and 
completion of pneumococcal conjugate vaccination schedule in children <5 years of age (CPR 
0.74, 95% CI 0.71–0.77) were associated with decreased risk of hospitalisation.
Conclusion—These results identify groups at high-risk for severe influenza who should be 
considered potential targets for influenza vaccination in South Africa and similar settings.
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1. Background
Influenza is a vaccine-preventable viral infection which can present with significant 
morbidity and mortality [1]. Globally, there are an estimated 3–5 million severe cases and 
300,000–500,000 deaths annually, of which the majority occur in low and middle income 
countries [2,3]. South Africa is a middle-income country with high incidence of HIV and 
tuberculosis. These underlying factors play a significant role in the presentation of seasonal 
influenza and its morbidity in Southern Africa.
National surveillance for influenza-associated hospitalizations in South Africa has estimated 
that 44% of patients admitted with acute respiratory infections testing positive for influenza 
are HIV-infected; in contrast, the national prevalence of HIV is 12% [4,5]. Studies from 
South Africa have suggested that high HIV prevalence in South Africa is associated with 
higher numbers of severe influenza-associated illness and thus more hospitalised cases [5–
8].
Though data are considered insufficient to allow prioritization of strategies for influenza 
prevention and control in most Sub-Saharan African countries [3], the South Africa 
government provides influenza vaccination free for those 6 months – <5 years of age, >65 
years of age, all pregnant women, healthcare workers and carers, and anyone >6 months of 
age with certain chronic underlying medical conditions [9,10]. Despite the existence of this 
policy for many years, procurement in the public immunization program is low and coverage 
remains approximately 5% [11]. Other than HIV, most known risk conditions for influenza-
associated hospitalisation, such as extremes of age and smoking, are derived from studies in 
developed countries with different health demographics or disease burden than sub-Saharan 
countries. The objective of this study was to identify risk factors and conditions which are 
associated with increased morbidity from influenza–associated severe respiratory illnesses in 
South Africa, a country with a background of high HIV endemicity, to guide influenza 
vaccination policy.
2. Methods
2.1. Study design
This study uses a case-population design to evaluate risk factors for influenza-associated 
hospitalisation using data from the Severe Acute Respiratory Illness (SARI) surveillance 
programme and health and demographic surveillance in South Africa from 2009 to 2012.
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2.2. Determination of risk factors among cases
The SARI surveillance programme has been previously described [5]. Briefly, SARI 
surveillance started in 2009 at 4 sentinel sites in South Africa located in 3 provinces: 
Gauteng Province (Chris Hani Baragwanath Academic Hospital, CHBAH), KwaZulu-Natal 
Province (Edendale Hospital), and Mpumalanga Province (Mapulaneng and Matikwana 
Hospitals). In 2010, one additional surveillance site was introduced in North West Province 
at Klerksdorp-Tshepong Hospital Complex (KTHC). A case of SARI was defined as a 
hospitalised person who had illness onset within 7 days of admission and met age-specific 
clinical inclusion criteria. These included children aged 2 days through <3 months who had 
physician-diagnosed sepsis or acute lower respiratory tract infection (LRTI); children aged 3 
months through <5 years with physician-diagnosed LRTI (e.g., bronchitis, bronchiolitis, 
pneumonia, or pleural effusion), and persons >5 years of age who met the World Health 
Organization (WHO) case definition for severe acute respiratory infection: an acute 
respiratory illness with a history of fever or measured fever of ≥38 °C and cough, with onset 
within the past 10 days, requiring hospitalisation [12].
Every patient with the above criteria, admitted on any weekday, was eligible for enrollment; 
however, adult patients at the sentinel site in Gauteng Province were enrolled only on 2 out 
of 5 weekdays due to the large number of admissions and limited resources. All eligible 
patients were approached for inclusion into the study.
Consenting patients were enrolled by completing a structured questionnaire on demographic 
characteristics and current and past medical history through interview and review of medical 
records. Nasopharyngeal and oropharyngeal swabs (for patients >5 years of age) or 
nasopharyngeal aspirates (for those <5 years of age) were collected and transported in viral 
transport media at 4–8 °C to the National Institute for Communicable Diseases (NICD) 
within 72 h. Specimens were tested using the reverse transcription real-time polymerase 
chain reaction (RT-PCR) for influenza A and B viruses. HIV infection status was determined 
from results of testing undertaken as part of standard of care or through anonymized linked 
dried blood spot specimen testing by HIV PCR for children <18 months of age and by 
enzyme-linked immuno-sorbent assay (ELISA) for persons >18 months of age. Enrolled 
patients were followed until discharge or death.
For our study, cases included all enrolled hospitalised SARI patients who tested positive for 
influenza by RT-PCR.
2.3. Determination of risk factors among referent population
Data on risk factors from South African national surveys were used for comparison and 
included the following (Table 1):
1. The National Census, 2011 [13]: This is the most recent national census with an 
estimated population of 51,770,560 individuals.
2. South African National Health and Nutrition Examination Survey 
(SANHANES), 2013 [4]: This was a national cross-sectional study conducted to 
provide critical information on the emerging epidemics of Non-Communicable 
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Diseases (NCDs) in South Africa and to analyse social, economic, behavioural 
and environmental determinants of NCDs.
3. South African National HIV Prevalence, Incidence and Behavioural Survey 
(SABSSM) 2008 & 2012 [14]: This was a multi-staged stratified cluster survey 
involving individuals of all ages living in South African households with 
statistical data on socio-behavioural and structural aspects that contribute to the 
spread of HIV infections in the population.
4. District Health Information System (DHIS), 2012 [15]: This is a system where 
the National Department of Health routinely collects health information from all 
the primary health care clinics throughout South Africa.
5. Risk Equalisation Fund for 2007 [16]: This study was done following the 
approval of the Social Health Insurance (SHI) policy by the South African 
National Department of Health to provide a baseline for cost evaluation of health 
policies and interventions.
Several risk factors are known to affect the risk of hospitalisation from influenza-associated 
SARI. The risk conditions evaluated for this study are limited to those which are prevalent in 
Africa and South Africa and for which we had data available; they are listed in Tables 1 and 
2.
2.4. Statistical analysis
The case-population study consists of comparing exposure to a condition or risk factor in 
patients presenting with a given disease or symptom (cases) with the exposure rate to this 
factor in the whole cohort or in the source population of cases [17]. Similar to the case-
control approach, the case-population approach measures the disproportionality of exposure 
between cases of a given disease and those exposed in a referent population, expressed as the 
Case Population Ratio (CPR) [17]. Our study compared the prevalence of demographic and 
medical conditions of cases enrolled in SARI surveillance with the national prevalence of 
these conditions to derive the age-specific and overall age-adjusted case-population ratios.
To estimate the actual number of influenza-associated SARI cases, the total number of 
enrolled SARI cases was adjusted for refusal to participate and non-enrollment in 3 of 5 
adult wards at CHBAH by age group using study logs that tracked all SARI cases (enrolled 
and not enrolled) admitted at the sentinel sites. We assumed that the prevalence of influenza-
associated cases and the prevalence of the exposure variables evaluated in this study among 
the influenza-associated cases were the same among enrolled and non-enrolled SARI cases. 
Using study logs, this adjustment (ranging from 1 to 7.8) was implemented because the 
proportion of cases enrolled varied each year by surveillance site depending on the age 
groups.
Cases were defined as patients hospitalised with SARI who tested positive for influenza as 
part of the SARI surveillance programme. The comparison population was the entire 
population of South Africa, identified from surveys and national health and demographic 
surveillance data. The exception to this was our analysis of the risk of influenza-associated 
hospitalisation from mining; since all of those who reported a history of mining were 
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working age adults from Gauteng Province, the comparison population for this potential risk 
factor was the Gauteng working population 15–65 years of age. The case-population ratio 
for factors associated with influenza-associated hospitalisation was estimated as follows:
where
a: number exposed in the cases b: number exposed in referent population
x: total number of cases y: total number of referent population
Under the null hypothesis, the ratio of the number exposed to the risk condition of interest to 
the total number of individual cases (a/x) should be the same as that in the source-population 
(b/y), or CPR = 1. A positive CPR suggests a positive association between the risk condition 
and increased hospitalisation due to influenza-associated SARI and vice versa. The age-
specific and age-adjusted CPR [with associated 95% confidence interval (CI)] for each 
exposure variable assessed in the study was estimated using log-binomial regression. The 
statistical analysis was implemented using STATA version 13.1 (Stata Corporation, College 
Station, Texas, USA).
2.5. Ethical considerations
The protocol of the SARI surveillance programme was approved by the University of the 
Witwatersrand Human Research Ethics Committee, Johannesburg, South Africa, Reference 
R14/41 Cohen and was deemed not to be research by the U.S. Centers for Disease Control 
and Prevention, Atlanta, USA. Data from national health and demographic surveys were 
publicly available.
3. Findings
3.1. Description of patients enrolled in the SARI programme
Between February 2009 and December 2012, a total of 18,590 patients were eligible and 
enrolled into SARI surveillance, of which 1425 (7.6%) tested positive for influenza virus. 
This was adjusted for age-specific differences in non-enrollment as described in the Methods 
to yield a total of 46,031 patients. After age-adjustment, the overall influenza detection rate 
was 7.9% (3646/46,031) with the highest detection rate in the 5–14 year age group (10.6%, 
119/1124) and the lowest in the 45–54 year age group (6.9%, 395/5652; Table 2). There was 
no significant change in age distribution in the different influenza seasons.
3.2. Factors associated with influenza hospitalisation
3.2.1. Age—The risk of hospitalisation for influenza was elevated in children <5 years of 
age (CPR 3.07; 95% CI 2.93–3.21) and adults ≥35 years of age (CPR 1.23, 95% CI 1.28–
1.18; Tables 2 and 3, Fig. 1) when compared to children aged 5–14 years.
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3.2.2. Social and economic factors—Among those aged 15 years and above, previous 
history of smoking, i.e., stopping use of all tobacco more than 4 weeks prior to presentation, 
was much more common among the influenza-associated SARI patients than in the referent 
population (CPR 3.82; 95% CI 3.50–4.16). Current alcohol use or within the past one month 
among adults (>15 years) did not suggest any increase in risk of hospitalisation (CPR 0.51, 
95% CI 0.47–0.55). Similarly, the prevalence of adults with a history of mining was higher 
among hospitalised influenza-associated SARI cases compared with the Gauteng working 
population (CPR 1.34: 95% CI 1.07–1.67).
3.2.3. Co-morbidities—Influenza-associated SARI patients were twice as likely to have 
been hospitalised in the past 12 months compared to the general population (CPR 2.07: 95% 
CI 1.92–2.23; Tables 2 and 3). HIV was found to be 4 times more prevalent among the 
influenza-associated SARI cases when compared to the general South African population 
(CPR 3.56; 95% CI 3.50–3.72). Furthermore, HIV co-infected influenza cases identified in 
SARI were more likely to be on highly active anti-retroviral therapy (HAART) than the 
referent HIV-infected population.
A history of active tuberculosis and a history of asthma were each twice as common among 
the influenza-associated SARI cases compared to the referent population (CPR 1.85; 95% CI 
1.68–2.02 and CPR 2.45; 95% CI 2.19–2.73, for tuberculosis and asthma, respectively). 
Among children aged <5 years, the proportion of children among SARI cases who 
completed the 3rd dose of PCV was less than the proportion seen in the general population 
(CPR 0.74; 95% CI 0.71–0.77). Malnutrition was not associated with increased risk of 
hospitalisation for influenza in our study population.
4. Discussion
Based on the strength of the associations we found in our analysis, we can classify the risk 
conditions into high risk (CPR > 2) or low risk (CPR ≤ 2). We can also classify risk 
conditions by their public health importance: high population prevalence (>20%) and low 
population prevalence (<20%). As shown in Table 3, the results of this study are consistent 
with current influenza vaccination policy in South Africa, which recommends influenza 
vaccination for children <5 years, adults >65 years and those with underlying medical 
conditions such as HIV [9]. Other risk groups that may be considered for influenza 
vaccination based on these results are those with asthma, those with a previous history of 
hospital admission in last 1 year, and those with a previous history of smoking of cigarettes. 
In addition, there may be benefit to targeted vaccination among miners and those with 
tuberculosis, but it may yield a smaller public health benefit compared with the other risk 
conditions. Sex, use of alcohol and malnutrition do not seem to be contributory factors to 
influenza-associated hospitalisations in severe respiratory infections in South Africa.
The increased prevalence of children (especially those <5 years) among influenza-associated 
hospitalised patients found in this study is similar to findings in studies from the U.S., the 
Philippines, Spain, China, Thailand and other European countries [18–23]. In a global 
pooled analysis, the risk of infection and hospitalisation was also found to be highest in 
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children [24]. This evidence has been the basis for consistent inclusion of these risk groups 
in the WHO recommended vaccination groups [3].
As has been shown in previous studies of this influenza surveillance data from South Africa, 
there is also an increase in prevalence among adults (>35 years) with increases at 35–44 
years and >65 years [5]. The increased prevalence among young adults may be due to a high 
prevalence of HIV infection, which suggests that vaccinating HIV-infected adults and 
children as well as the elderly may be a good strategy.
HIV is the most common underlying risk condition among the SARI cohort. In contrast to 
HIV non-endemic countries like United States [26] and Spain [27], HIV has been implicated 
as a risk factor for influenza hospitalisation and severe disease in highly endemic settings 
like South Africa [5] and Kenya [28]. Cohen et al. demonstrated that HIV-infected patients 
had a 4–8 times greater hospitalisation incidence, longer inpatient hospital admission by 2–7 
days and more deaths when compared to HIV-uninfected patients [5]. HIV infection is also 
associated with increased magnitude and prolonged duration of influenza viral shedding 
[29]. Unexpectedly, we found that more HIV-influenza co-infected hospitalised patients 
were on HAART compared to HIV-infected individuals in the general population. This could 
be from confounding factors like staging of HIV infection or non-adherence to treatment, 
which we did not have data for in this analysis. It could also be due to under-reporting of 
HAART utilisation in the general population compared with the SARI cohort.
This study found a 4-fold higher prevalence of previous smoking among hospitalised SARI 
patients than in the general population. Other studies have also identified smoking as a risk 
factor for increased influenza severity [30] but many were not statistically significant after 
adjusting for confounders [27,31]. Our findings could be explained by the fact that most of 
the SARI patients are female, who are more likely to be HIV-infected, and patients may quit 
smoking once sick, prior to hospital admission. In many studies, rates of hospitalisation 
from seasonal influenza viruses seem to be higher in males than females [32–36]. The 
reverse was found in this study, which could be as a result of high HIV infection prevalence 
among females (70% of SARI cases) predisposing them to influenza infection and 
hospitalisation. Our study suggested that consumption of alcohol currently or within the past 
month was associated with a reduction in risk of hospitalisation from influenza. There are 
few studies on seasonal influenza and alcohol use to explain this finding, and we were 
unable to adjust for duration and intensity of alcohol consumption which may affect these 
findings.
The increased risk associated with mining in this study is similar to an U.S. study from the 
1918 pandemic which estimated that coal-miners with influenza-associated pneumonia had a 
44% mortality rate compared to a 30% overall death rate among all males aged 15 years and 
over in Ohio [37]. Mining has been associated with tuberculosis in South Africa [38,39], and 
active tuberculosis may be a risk factor for increased influenza severity [40]. Our results 
show that history of diagnosis with active tuberculosis was almost double within the SARI 
cohort compared to the expected national estimate, which is consistent with other studies 
from South Africa [41].
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As we found in our study, a study in Netherlands showed that previous history of 
hospitalisation in the past year is an independent risk factor for influenza-associated 
respiratory hospitalisation [42]. Likewise, among the elderly in Manitoba, Canada, 
approximately 40% of all those discharged for influenza-associated conditions and 
approximately 65% of those who died had been discharged from hospital during the 
previous vaccination season [43]. Malnutrition does not attain a statistically significant CPR 
in our study consistent with mixed results reported by others [44–48].
Our data suggests a 25% decrease in prevalence of influenza-associated respiratory 
hospitalizations among children who completed their pneumococcal vaccination compared 
to the referent. This is consistent with a double blind, randomised placebo-controlled trial in 
South Africa which showed that pneumococcal vaccination in children not only prevents 
invasive pneumococcal diseases but also prevents 31% of pneumonias associated with 
respiratory viruses in children in hospital [49]. This is likely due to the well-described 
increased risk of pneumococcal disease following influenza infection, which could be 
prevented by influenza vaccination.
This study has some limitations. Firstly, the SARI cohort may not be a geographically and 
racially representative sample of the entire South African population, which is what was 
available as the referent population from the national surveys. CHBAH is one of the four 
sentinel surveillance sites in this study and contributed 62% of the entire SARI data. 
Secondly, the use of an ecological referent comparison did not allow for control of 
individual level confounding to derive an unbiased effect estimate of each risk factor, as we 
are restricted to basic socio-demographic variables like sex and age. Thirdly, data in SARI 
and South African population surveys were obtained using different methodologies. Clinical 
data among SARI cases was obtained through oral interviews and review of hospital records, 
whereas the national health surveys were carried out without access to participant’s hospital 
records. This review of the medical records could have led to identification of more risk 
conditions in the SARI cohorts causing overestimation between the two groups, such as with 
HAART. Since our comparison data were derived for demographic surveys which are 
reported and summarised in certain age groups of relevance, analysis into smaller age groups 
were not be possible which could yield more specific groups at highest risk for prioritization 
of the limited available vaccine. Lastly, pregnant women have been demonstrated in several 
studies to have increased severity of influenza disease and rate of hospitalisation [5,24,50]. 
Since few pregnant women were enrolled in our study because review of admissions to 
maternity wards during recruitment was not always consistent, no risk analysis was carried 
out in this risk group in our study.
Despite these limitations, our results were consistent with existing medical literature from 
other contexts in identifying age, previous smoking history, HIV, tuberculosis, asthma, 
mining and previous history of hospital admission as factors influencing influenza-
associated hospitalisation.
In conclusion, the findings from this study can potentially help policy-makers make 
evidence-based decisions on how to target influenza treatment and prevention programs, 
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such as vaccination, and can lead to more effective allocation of resources within countries 
like South Africa with a high prevalence of HIV.
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Fig. 1. 
Case Population Ratio and 95% confidence intervals by age group of influenza-associated 
SARI patients compared to South African population.
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Table 3
Identification of priority conditions for influenza vaccination based on the strength of association and 
population prevalence of the various risk conditions identified in this study.
Prevalence in the general population
Low < 10% High > 10%
Case Population Ratio (CPR) Low < 2.0 Tuberculosis (Prevalence 6%, CPR 1.85)
History of mining (3%, 1.34)
Elderly 65+ years (5%, 1.27)
High 2.0 Previous history of smoking (>15 years) HIV (12%, 3.61)
(4%, 3.82) Children < 5 years (11%, 3.07)
Asthma (4%, 2.45)
Previous history of admission in the past 1 year (9%, 2.07)
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